Public-facility patients also had 38% lower odds of receiving a clinician recommendation for the vaccine than those at private centers.
Children with a vaccine-hesitant parent varied by vaccine: 56% for COVID, 31% for flu, 30% for HPV, and 12% for other childhood illnesses.
In women offered HPV vaccination at age 12 and/or 13 years, rates of cervical cancer and precancerous lesions were, respectively, 84% and 94% lower.
Compared to last year, cholera cases are down 32%, but deaths are up 14%.
Uptake is even lower in men, Hispanic respondents, and people with less education.
There was no significant association between HPV, metabolic syndrome, and death in men.
The new efforts hinge on broader HPV vaccine access, along with better screening and treatment.
Safety concerns were more prevalent in higher income parents, while knowledge gaps and lack of provider recommendation were more common in their lower income peers.
Girls (43%) were more likely than boys (35%) to have received one or more HPV vaccine doses.
The association was stronger in obese women than in those of a healthy weight.
